🇺🇸 FDA
Pipeline program

Tasimelteon Oral Suspension

VP-VEC-162-3108

Phase 3 small_molecule active

Quick answer

Tasimelteon Oral Suspension for Insomnia Disorder is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Insomnia Disorder
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials